{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T12:44:24Z","timestamp":1770468264047,"version":"3.49.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-71143-6","type":"journal-article","created":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T09:02:06Z","timestamp":1725181326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A real world analysis of secondary BRAF variations after targeted therapy resistance in driver gene positive NSCLC"],"prefix":"10.1038","volume":"14","author":[{"given":"DuJiang","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KaiBo","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KaiLai","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ZhongSheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"XuanHong","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YanJun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,1]]},"reference":[{"issue":"3","key":"71143_CR1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.jtho.2016.11.2231","volume":"12","author":"C-C Ho","year":"2017","unstructured":"Ho, C.-C. et al. Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib. J. Thorac. Oncol. 12(3), 567\u2013572. https:\/\/doi.org\/10.1016\/j.jtho.2016.11.2231 (2017).","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"71143_CR2","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1007\/s00432-020-03239-1","volume":"146","author":"Y Mu","year":"2020","unstructured":"Mu, Y. et al. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: Mechanisms and clinical outcomes. J. Cancer Res. Clin. Oncol. 146(9), 2427\u20132433. https:\/\/doi.org\/10.1007\/s00432-020-03239-1 (2020).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"71143_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx703","author":"D Westover","year":"2018","unstructured":"Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M. & Paz-Ares, L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Annal. Oncol. https:\/\/doi.org\/10.1093\/annonc\/mdx703 (2018).","journal-title":"Annal. Oncol."},{"key":"71143_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.01.1147","author":"W Fang","year":"2021","unstructured":"Fang, W. et al. Molecular characteristics of BRAF mutations in EGFR mutant NSCLC after progression on EGFR TKIs and response to combination targeted therapy. J. Thoracic Oncol. https:\/\/doi.org\/10.1016\/j.jtho.2021.01.1147 (2021).","journal-title":"J. Thoracic Oncol."},{"key":"71143_CR5","doi-asserted-by":"publisher","unstructured":"Dankner, M., Rose, A. A. N., Rajkumar, S., Siegel, P. M. & Watson, I. R. Classifying BRAF alterations in cancer: New rational therapeutic strategies for actionable mutations. https:\/\/doi.org\/10.1038\/s41388-018-0171-x.","DOI":"10.1038\/s41388-018-0171-x"},{"issue":"7666","key":"71143_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nature23291","volume":"548","author":"Z Yao","year":"2017","unstructured":"Yao, Z. et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 548(7666), 234\u2013238. https:\/\/doi.org\/10.1038\/nature23291 (2017).","journal-title":"Nature"},{"issue":"4","key":"71143_CR7","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/annonc\/mdy009","volume":"29","author":"YS Li","year":"2018","unstructured":"Li, Y. S. et al. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: A new medium of liquid biopsy. Ann. Oncol. 29(4), 945\u2013952. https:\/\/doi.org\/10.1093\/annonc\/mdy009 (2018).","journal-title":"Ann. Oncol."},{"key":"71143_CR8","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ebiom.2019.04.030","volume":"43","author":"Y-C Zhang","year":"2019","unstructured":"Zhang, Y.-C. et al. Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial. EBioMedicine 43, 180\u2013187. https:\/\/doi.org\/10.1016\/j.ebiom.2019.04.030 (2019).","journal-title":"EBioMedicine"},{"key":"71143_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00011","volume":"1","author":"D Chakravarty","year":"2017","unstructured":"Chakravarty, D. et al. OncoKB: A precision oncology knowledge base. JCO Precision Oncol. 1, 1\u201316. https:\/\/doi.org\/10.1200\/PO.17.00011 (2017).","journal-title":"JCO Precision Oncol."},{"key":"71143_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li, M. M. et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the association for molecular pathology, American society of clinical oncology, and College of American pathologists. J. Mol. Diagn. 19, 4\u201323. https:\/\/doi.org\/10.1016\/j.jmoldx.2016.10.002 (2017).","journal-title":"J. Mol. Diagn."},{"issue":"3","key":"71143_CR11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/cncr.29042","volume":"121","author":"LC Villaruz","year":"2015","unstructured":"Villaruz, L. C. et al. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the LUng CAncer Mutation Consortium. Cancer 121(3), 448\u2013456. https:\/\/doi.org\/10.1002\/cncr.29042 (2015).","journal-title":"Cancer"},{"issue":"26","key":"71143_CR12","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1200\/JCO.2011.35.9638","volume":"29","author":"A Marchetti","year":"2011","unstructured":"Marchetti, A. et al. Clinical features and outcome of patients with non\u2013small-cell lung cancer harboring BRAF mutations. JCO 29(26), 3574\u20133579. https:\/\/doi.org\/10.1200\/JCO.2011.35.9638 (2011).","journal-title":"JCO"},{"issue":"3","key":"71143_CR13","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/cam4.1014","volume":"6","author":"X Ding","year":"2017","unstructured":"Ding, X. et al. Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation. Cancer Med. 6(3), 555\u2013562. https:\/\/doi.org\/10.1002\/cam4.1014 (2017).","journal-title":"Cancer Med."},{"key":"71143_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00172","volume":"2","author":"Y Sheikine","year":"2018","unstructured":"Sheikine, Y. et al. BRAF in lung cancers: Analysis of patient cases reveals recurrent BRAF mutations, fusions, kinase duplications, and concurrent alterations. JCO Precis. Oncol. 2, 1\u201315. https:\/\/doi.org\/10.1200\/PO.17.00172 (2018).","journal-title":"JCO Precis. Oncol."},{"issue":"2","key":"71143_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria, J.-C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378(2), 113\u2013125. https:\/\/doi.org\/10.1056\/NEJMoa1713137 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"71143_CR16","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.21037\/atm-21-3570","volume":"9","author":"P Peng","year":"2021","unstructured":"Peng, P. et al. Co-mutations of epidermal growth factor receptor and BRAF in Chinese non-small cell lung cancer patients. Ann. Transl. Med. 9(16), 1321\u20131321. https:\/\/doi.org\/10.21037\/atm-21-3570 (2021).","journal-title":"Ann. Transl. Med."},{"key":"71143_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100348","author":"X-W Wei","year":"2022","unstructured":"Wei, X.-W. et al. Characteristics of and treatment strategies for advanced EGFR-mutant NSCLC with concomitant BRAF variations. JTO Clin. Res. Rep. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100348 (2022).","journal-title":"JTO Clin. Res. Rep."},{"issue":"3","key":"71143_CR18","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/1759-7714.14295","volume":"13","author":"M Sun","year":"2022","unstructured":"Sun, M. et al. Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions. Thoracic Cancer 13(3), 514\u2013516. https:\/\/doi.org\/10.1111\/1759-7714.14295 (2022).","journal-title":"Thoracic Cancer"},{"key":"71143_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2020.05.018","volume":"146","author":"R Shi","year":"2020","unstructured":"Shi, R. et al. BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer. Lung Cancer 146, 78\u201385. https:\/\/doi.org\/10.1016\/j.lungcan.2020.05.018 (2020).","journal-title":"Lung Cancer"},{"issue":"5","key":"71143_CR20","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jtho.2018.12.038","volume":"14","author":"M Vojnic","year":"2019","unstructured":"Vojnic, M. et al. Acquired BRAF rrearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers. J. Thor. Oncol. 14(5), 802\u2013815. https:\/\/doi.org\/10.1016\/j.jtho.2018.12.038 (2019).","journal-title":"J. Thor. Oncol."},{"issue":"1","key":"71143_CR21","doi-asserted-by":"publisher","first-page":"186","DOI":"10.21037\/tcr-22-2060","volume":"12","author":"W-M Kong","year":"2023","unstructured":"Kong, W.-M., Guo, Y.-J., Ma, J. & Shi, C. BTN2A1-BRAF fusion may be a novel mechanism of resistance to osimertinib in lung adenocarcinoma: A case report. Transl. Cancer Res. 12(1), 186\u2013193. https:\/\/doi.org\/10.21037\/tcr-22-2060 (2023).","journal-title":"Transl. Cancer Res."},{"key":"71143_CR22","doi-asserted-by":"publisher","first-page":"1124949","DOI":"10.3389\/fonc.2023.1124949","volume":"13","author":"W Kian","year":"2023","unstructured":"Kian, W. et al. Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to osimertinib. Front. Oncol. 13, 1124949. https:\/\/doi.org\/10.3389\/fonc.2023.1124949 (2023).","journal-title":"Front. Oncol."},{"key":"71143_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000024917","author":"A Sui","year":"2021","unstructured":"Sui, A. et al. BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma: A case report. Medicine https:\/\/doi.org\/10.1097\/MD.0000000000024917 (2021).","journal-title":"Medicine"},{"key":"71143_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100377","author":"S Ren","year":"2021","unstructured":"Ren, S. et al. Crizotinib resistance conferred by BRAF V600E mutation in non-small cell lung cancer harboring an oncogenic ROS1 fusion. Cancer Treat. Res. Commun. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100377 (2021).","journal-title":"Cancer Treat. Res. Commun."},{"key":"71143_CR25","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00551","author":"NP Giustini","year":"2022","unstructured":"Giustini, N. P. et al.  Resistance to EGFR tyrosine kinase inhibitor therapy in non\u2013small-cell lung cancer via newly acquired targetable oncogenic driver alterations with an emphasis on BRAF: Case series and literature review of treatment. JCO Precisio.  Oncolog. https:\/\/doi.org\/10.1200\/PO.21.00551 (2022).","journal-title":"JCO Precisio. Oncolog."},{"key":"71143_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.lungcan.2020.06.004","volume":"146","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Acquired BRAF N581S mutation mediated resistance to gefitinib and responded to dabrafenib plus trametinib. Lung Cancer 146, 355\u2013357. https:\/\/doi.org\/10.1016\/j.lungcan.2020.06.004 (2020).","journal-title":"Lung Cancer"},{"key":"71143_CR27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.lungcan.2021.06.025","volume":"159","author":"C Mauclet","year":"2021","unstructured":"Mauclet, C., Collard, P., Ghaye, B., Hoton, D. & Nana, F. A. Tumor response to EGFR\/BRAF\/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAFV600 mutation as an acquired resistance mechanism. Lung Cancer. 159, 42\u201344. https:\/\/doi.org\/10.1016\/j.lungcan.2021.06.025 (2021).","journal-title":"Lung Cancer"},{"issue":"12","key":"71143_CR28","doi-asserted-by":"publisher","first-page":"e2115","DOI":"10.1002\/onco.13979","volume":"26","author":"J Li","year":"2021","unstructured":"Li, J., Wang, Q., Ge, J., Tian, Y. & Yao, W. BRAF V600E mediates crizotinib resistance and responds to dabrafenib and trametinib in a ROS1-rearranged non-small cell lung cancer: A case report. Oncol. 26(12), e2115\u2013e2119. https:\/\/doi.org\/10.1002\/onco.13979 (2021).","journal-title":"Oncol."},{"key":"71143_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.lungcan.2019.10.014","volume":"139","author":"F Zhou","year":"2020","unstructured":"Zhou, F., Zhao, W., Chen, X., Zhang, J. & Zhou, C. Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAFV600E mutation. Lung Cancer 139, 219\u2013220. https:\/\/doi.org\/10.1016\/j.lungcan.2019.10.014 (2020).","journal-title":"Lung Cancer"},{"key":"71143_CR30","doi-asserted-by":"publisher","unstructured":"Zeng, R. et al. EGFR\/BRAF\/MEK Co-Inhibition for EGFR-Mutated Lung Adenocarcinoma Patients with an Acquired BRAFV600E Mutation: A Case Report and Review of Literature. CDR 2021. https:\/\/doi.org\/10.20517\/cdr.2021.98 (2021).","DOI":"10.20517\/cdr.2021.98"},{"key":"71143_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2021.100192","author":"O Valet","year":"2021","unstructured":"Valet, O. et al. Response to the combination of osimertinib, dabrafenib, and trametinib in leptomeningitis from EGFR-mutant NSCLC with acquired BRAF V600E mutation: A case report. JTO Clin. Res. Rep. https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100192 (2021).","journal-title":"JTO Clin. Res. Rep."},{"key":"71143_CR32","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.2147\/CMAR.S387211","volume":"14","author":"D Li","year":"2022","unstructured":"Li, D. et al. Combined lorlatinib, dabrafenib, and trametinib treatment for ROS1-rearranged advanced non-small-cell lung cancer with a lorlatinib-induced BRAF V600E mutation: A case report. CMAR 14, 3175\u20133179. https:\/\/doi.org\/10.2147\/CMAR.S387211 (2022).","journal-title":"CMAR"},{"issue":"10422","key":"71143_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","volume":"403","author":"CJ Tsai","year":"2024","unstructured":"Tsai, C. J. et al. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (consolidative use of radiotherapy to block [CURB] oligoprogression): An open-label, randomised, controlled, phase 2 study. Lancet, 403(10422), 171\u2013182. https:\/\/doi.org\/10.1016\/S0140-6736(23)01857-3 (2024).","journal-title":"Lancet"},{"key":"71143_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lungcan.2017.06.014","volume":"111","author":"C Labb\u00e9","year":"2017","unstructured":"Labb\u00e9, C. et al. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung Cancer 111, 23\u201329. https:\/\/doi.org\/10.1016\/j.lungcan.2017.06.014 (2017).","journal-title":"Lung Cancer"},{"issue":"9","key":"71143_CR35","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1097\/CAD.0000000000001367","volume":"33","author":"S Li","year":"2022","unstructured":"Li, S., Lin, X., Sun, S., Li, S. & Zhou, C. Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-Type (BRAF) p.D594N mutation: A case report. Anti-Cancer Drugs 33(9), 963\u2013965 (2022).","journal-title":"Anti-Cancer Drugs"},{"issue":"11","key":"71143_CR36","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/j.jtho.2017.07.017","volume":"12","author":"A Bearz","year":"2017","unstructured":"Bearz, A., De Carlo, E., Doliana, R. & Schiappacassi, M. Acquired BRAF V600E mutation as resistant mechanism after treatment with third-generation EGFR tyrosine kinase inhibitor. J. Thoracic Oncol. 12(11), e181\u2013e182. https:\/\/doi.org\/10.1016\/j.jtho.2017.07.017 (2017).","journal-title":"J. Thoracic Oncol."},{"issue":"10","key":"71143_CR37","doi-asserted-by":"publisher","first-page":"e174","DOI":"10.1016\/j.jtho.2020.07.007","volume":"15","author":"I Dagogo-Jack","year":"2020","unstructured":"Dagogo-Jack, I. Durable response to Dabrafenib combined with trametinib in a patient with NSCLC harboring a BRAF G469A mutation. J. Thoracic Oncol. 15(10), e174\u2013e176. https:\/\/doi.org\/10.1016\/j.jtho.2020.07.007 (2020).","journal-title":"J. Thoracic Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71143-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71143-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71143-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T09:02:35Z","timestamp":1725181355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-71143-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["71143"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-71143-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,1]]},"assertion":[{"value":"21 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of Zhejiang Cancer Hospital (approval number IRB-2020\u2013324). All participants signed informed consent forms, and the study adhered to the ethical principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"20302"}}